Helus Pharma: A Buy Ahead Of The HLP003 Phase 3 Readout

Helus Pharma is expected to report results from its phase 3 trial of HLP003 in the coming weeks.

The company's stock price has been volatile recently, but analysts are optimistic about the potential of HLP003.

Want to stay up to date with the world events at sea or at home?